Edinburgh Clinical Trials
ECTU logo

TOPaZ

Treatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic acid

TOPaZ is a randomised open-label clinical trial for people with osteogenesis imperfecta (OI). The study aims to investigate whether a two-year spell of treatment with a drug called teriparatide (TPTD) followed by treatment with another drug called Zoledronic acid (ZA) reduces the risk of broken bones occurring in people with OI.

 

Chief Investigator: Prof. Stuart Ralston

Number and location of participating sites (by region/ country): 25 UK and Republic of Ireland sites

EudraCT number: 2016-003228-22

ISRCTN number: 15313991

Funder: NIHR Efficacy and Mechanism Evaluation Programme

 

Start and End date:

Of grant award - Nov 2016-April 2023

Of recruitment

 

Current Status: In set up

 

Trial Website: The TOPaZ Trial

 

Sponsor: ACCORD http://www.accord.ed.ac.uk/

Chief Investigator: Professor Stuart Ralston, Molecular Medicine Centre, Institute of Genetics and Molecular Medicine, Western General Hospital, Edinburgh, EH4 2XU

Trial manager: Dr Holly Ennis (topaz.trial@ed.ac.uk

 

ECTU Involvement: Trial management / Statistics / Database and randomisation service provision.

(UKCRC)

TOPaZ study logo